Literature DB >> 10969972

CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.

I T Forbes1, D G Cooper, E K Dodds, D M Hickey, R J Ife, M Meeson, M Stockley, T A Berkhout, J Gohil, P H Groot, K Moores.   

Abstract

A weak HTS hit at the CCR2B receptor has been converted into a potent antagonist by array SAR studies. Selectivity over the closely related CCR5 receptor is also achieved.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10969972     DOI： 10.1016/s0960-894x(00)00347-4

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  4 in total

1.  Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.

Authors:  P C Rummel; K N Arfelt; L Baumann; T J Jenkins; S Thiele; H R Lüttichau; A Johnsen; J Pease; S Ghosh; R Kolbeck; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.

Authors:  Michelle B Kim; Kyle E Giesler; Yesim A Tahirovic; Valarie M Truax; Dennis C Liotta; Lawrence J Wilson
Journal:  Expert Opin Investig Drugs       Date:  2016-12       Impact factor: 6.206

Review 3.  G protein-coupled receptors--recent advances.

Authors:  Dorota Latek; Anna Modzelewska; Bartosz Trzaskowski; Krzysztof Palczewski; Sławomir Filipek
Journal:  Acta Biochim Pol       Date:  2012-12-18       Impact factor: 2.149

4.  3D-QSAR studies on CCR2B receptor antagonists: Insight into the structural requirements of (R)-3-aminopyrrolidine series of molecules based on CoMFA/CoMSIA models.

Authors:  Swetha Gade; Shaik Mahmood
Journal:  J Pharm Bioallied Sci       Date:  2012-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.